Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) announced it will present clinical EEG data from its Phase 1 a/b trial of ATH-1017 at the Alzheimer’s Association International Conference 2021 (AAIC), taking place July 26-30, 2021. The presentation, featuring data on neurophysiological changes in Alzheimer’s patients, will be accessible on the AAIC platform and Athira's website. ATH-1017 aims to enhance the activity of Hepatocyte Growth Factor (HGF) to combat neurodegeneration, including Alzheimer's and Parkinson's dementia. The company is committed to advancing therapeutic solutions for cognitive improvement.

Athira Pharma announced the enrollment of patients in an open-label extension study for ATH-1017, a treatment for mild-to-moderate Alzheimer’s disease, following ongoing Phase 2/3 trials, LIFT-AD and ACT-AD. This extension allows for up to 26 weeks of additional therapy, generating crucial data on safety and efficacy. ATH-1017 aims to enhance cognitive function by targeting Hepatocyte Growth Factor (HGF) and its receptor, MET. Positive Phase 1a/b results showed improvement in cognitive metrics, and patent protection for ATH-1017 extends until June 2037.

A class action lawsuit has been filed against Athira Pharma (NASDAQ: ATHA) by Keller Rohrback and Longman Law, P.C. The case follows allegations of misrepresentation in Athira's IPO registration statement, particularly concerning CEO Dr. Leen Kawas. After Dr. Kawas was placed on temporary leave due to allegations of falsifying research results, Athira's stock plummeted nearly 40% from $18.24 to $11.15 per share, below the IPO price of $17.00. The lawsuit seeks remedies under the Securities Act of 1933 for affected shareholders.

Washington State University has initiated a review of potential research misconduct claims involving former student Leen Kawas, now the CEO of Athira Pharma (NASDAQ: ATHA). The Athira board has placed Kawas on temporary leave while it conducts its own investigation into her doctoral research. WSU emphasizes its commitment to high ethical standards in research and is adhering to its Executive Policy 33 for handling such allegations. Further details will be withheld until the review is concluded.

Athira Pharma has placed Leen Kawas on temporary leave pending a review related to her doctoral research at Washington State University. Mark Litton, currently COO, will take over leadership responsibilities. An independent committee has been formed for the review. Despite this, the company remains confident in its lead drug ATH-1017, which has shown promising results in clinical trials for improving cognitive functions and addressing neurodegenerative diseases. Athira emphasizes its commitment to scientific integrity amidst this review process.

Athira Pharma (NASDAQ: ATHA) appointed Rachel Lenington as Chief Technology Officer, effective June 14, 2021. Lenington brings over 20 years of experience from organizations like Seagen Inc and the Bill & Melinda Gates Foundation. Her expertise in R&D, drug development, and commercialization is expected to bolster Athira's efforts in neurodegenerative disease treatments. CEO Leen Kawas expressed optimism about her leadership enhancing the company's product strategies. Athira focuses on developing small molecules to restore neuronal health, notably its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s dementia.

Athira Pharma (NASDAQ: ATHA) announced its participation in two upcoming investor conferences: the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET and the Raymond James Human Health Innovation Conference on June 21, 2021, at 1:20 PM ET. Management will engage in discussions about neurodegenerative diseases, focusing on new therapeutic targets for conditions like Alzheimer’s and Parkinson’s. Webcasts of the presentations will be available on the company’s website for 30 days post-event.

Athira Pharma, Inc. (NASDAQ: ATHA) has appointed Mark Worthington as General Counsel, effective June 1, 2021. Worthington brings extensive legal experience from 24 years at Summit Law Group, particularly in corporate finance and governance. His role is expected to bolster Athira’s strategic business growth, as cited by CEO Leen Kawas. Athira is focused on developing therapies aimed at neurodegenerative disorders, with its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s disease.

Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.